Bio-Gate and Ossis Expand into New Markets with Implant Coatings

Bio-Gate AG, a provider of innovative technologies and individual solutions for health and hygiene, will introduce and market the HyProtectTM coating in further markets in the future via its long-standing partner Ossis Ltd. from New Zealand. The cooperation relates primarily to individual case supplies in human medicine with orthopaedic revision implants.
Bio-Gate has already been working successfully with Ossis for several years, coating revision implants with HyProtectTM technology. The titanium implants coated by Bio-Gate are manufactured by Ossis using 3D printing and are mainly used in orthopaedic revisions of patients who are particularly at risk of infection. Ossis recently accepted a takeover offer from the global medical technology manufacturer Zimmer Biomet. The cooperation with Bio-Gate is to be continued unchanged due to the high quality of the HyProtectTM coatings in the compassionate care sector and even extended to other regions worldwide through the now global network.
The titanium implants coated by Bio-Gate have already been used in a three-digit number of individual case restorations. Single-case restorations with antimicrobial implants are mainly carried out on patients at risk of infection with previous orthopaedic revisions or on cancer patients. This is because in these patient groups new infections can lead to amputations or even have life-threatening consequences. Worldwide, patients in the EU, Switzerland, Great Britain, New Zealand, Australia and the USA have been treated with implants coated by Bio-Gate. In Germany, for example, implants have already been coated for high-risk patients at the Berufsgenossenschaftliche Uniklinik Murnau, the Uniklinik Regensburg and the Uniklinik Gießen.
The successful individual case restorations are arousing the interest of international clinics and surgeons. In the meantime, Bio-Gate has extensive data material from medical technology products implanted in humans and can prove the high quality of the HyProtectTM coating in practical applications. Together with positive scientific publications, the successful operations have already led to hospitals explicitly requesting implants with Bio-Gate's coating from manufacturers for high-risk patients.
Thomas Konradt, Director of Business Development at Bio-Gate AG: "We are very pleased that our cooperation partner wants to take advantage of the new, worldwide marketing opportunities for our HyProtectTM coating through the expanded network with us. The high quality of the HyProtectTM coating, which greatly reduces the risk of re-infection in patients who are particularly at risk of infection, will thus become even more widely known. In addition, the amount of implants manufactured using the 3D printing process is likely to increase in the future. This will increase the number of individual case restorations and is extremely helpful in developing our medical technology business into a growth driver."

Autor(en): mak

Alle News News